Education
About Us
Working with TipRanks
Follow Us
Maze Therapeutics, Inc. (MAZE)
:MAZE
MAZE Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MAZE Stock 12 Month Forecast
Average Price Target
$26.75
▲(100.37% Upside)
| Highest Price Target$34.00 | Average Price Target$26.75 | Lowest Price Target$17.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$28
Buy
109.74%
Upside
Reiterated
08/13/25
Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial HealthWe are updating our model to reflect Maze's (MAZE, OP) 2Q25 financial results and corporate update; data with MZE782 remain on track for this quarter, followed by initial HORIZON (MZE829) results in 1Q26. It has been another quarter of execution for Maze, which continues to advance its platform of novel, small-molecule precision medicines across renal, cardiovascular, and related metabolic diseases (see our initiation here for additional detail). For lead asset MZE829, an inhibitor of apolipoprotein L1 (APOL1), enrollment continues to progress in the Ph.2 HORIZON study (NCT06830629). This trial includes a broad population of patients with APOL1 kidney disease (AKD), including those with diabetes, non-diabetic kidney disease, and severe focal segmental glomerulosclerosis (FSGS). We continue to expect initial proof- of-concept data in the first quarter of 2026.
H.C. Wainwright
$34
Buy
154.68%
Upside
Reiterated
08/13/25
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782We think that safety risks appear minimal, given that patients with Hartnup disease (complete SLC6A19 loss) experience only mild symptoms. In preclinical animal PKU and CKD models, MZE782 drove robust phenylalanine excretion, reduced albuminuria, and preserved proximal-tubule integrity, strongly supporting its mechanism of action, and supports the ongoing Phase 1 study and potential Phase 2 studies to validate the molecule for both PKU and CKD respectively, in our opinion.
TD Cowen
―
Buy
―
Reiterated
08/13/25
TR | OpenAI - 4o
―
Hold
―
Initiated
04/11/25
Guggenheim
$19
Buy
42.32%
Upside
Initiated
02/25/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$28
Buy
109.74%
Upside
Reiterated
08/13/25
Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial HealthWe are updating our model to reflect Maze's (MAZE, OP) 2Q25 financial results and corporate update; data with MZE782 remain on track for this quarter, followed by initial HORIZON (MZE829) results in 1Q26. It has been another quarter of execution for Maze, which continues to advance its platform of novel, small-molecule precision medicines across renal, cardiovascular, and related metabolic diseases (see our initiation here for additional detail). For lead asset MZE829, an inhibitor of apolipoprotein L1 (APOL1), enrollment continues to progress in the Ph.2 HORIZON study (NCT06830629). This trial includes a broad population of patients with APOL1 kidney disease (AKD), including those with diabetes, non-diabetic kidney disease, and severe focal segmental glomerulosclerosis (FSGS). We continue to expect initial proof- of-concept data in the first quarter of 2026.
H.C. Wainwright
$34
Buy
154.68%
Upside
Reiterated
08/13/25
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782We think that safety risks appear minimal, given that patients with Hartnup disease (complete SLC6A19 loss) experience only mild symptoms. In preclinical animal PKU and CKD models, MZE782 drove robust phenylalanine excretion, reduced albuminuria, and preserved proximal-tubule integrity, strongly supporting its mechanism of action, and supports the ongoing Phase 1 study and potential Phase 2 studies to validate the molecule for both PKU and CKD respectively, in our opinion.
TD Cowen
―
Buy
―
Reiterated
08/13/25
TR | OpenAI - 4o
―
Hold
―
Initiated
04/11/25
Guggenheim
$19
Buy
42.32%
Upside
Initiated
02/25/25
Best Analysts Covering Maze Therapeutics, Inc.
1 Month
xxx
Success Rate
4/5 ratings generated profit
Average Return
+14.44%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +14.44% per trade.
3 Months
xxx
Success Rate
4/5 ratings generated profit
Average Return
+12.36%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +12.36% per trade.
1 Year
Success Rate
5/5 ratings generated profit
Average Return
+20.68%
reiterated a buy rating 4 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +20.68% per trade.
2 Years
xxx
Success Rate
5/5 ratings generated profit
Average Return
+20.68%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +20.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MAZE Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
3
3
4
6
Buy
2
2
2
3
4
Hold
1
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
6
6
7
10
Each month's total comprises the sum of three months' worth of ratings.
MAZE Financial Forecast
MAZE Stock Forecast FAQ
What is MAZE’s average 12-month price target, according to analysts?
Based on analyst ratings, Maze Therapeutics, Inc.’s 12-month average price target is 26.75.
What is MAZE’s upside potential, based on the analysts’ average price target?
Maze Therapeutics, Inc. has 100.37% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MAZE a Buy, Sell or Hold?
Maze Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Maze Therapeutics, Inc.’s price target?
The average price target for Maze Therapeutics, Inc. is 26.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $17.00. The average price target represents 100.37% Increase from the current price of $13.35.
The highest analyst price target is $34.00 ,the lowest forecast is $17.00. The average price target represents 100.37% Increase from the current price of $13.35.
What do analysts say about Maze Therapeutics, Inc.?
Maze Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of MAZE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.